Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

BioCryst Pharmaceuticals stock climbs 9% on strong Orladeyo sales, 2025 revenue guidance boost, and market dominance. See why ...

The increasing occurrence of genetic disorders is a major factor fueling the demand for oligonucleotide synthesis, as these molecules are essential for gene therapies and diagnostics aimed at ...

Following a more than two-year-long hold, Entrada Therapeutics can get its Duchenne muscular dystrophy candidate back on ...

One of Australia's biggest pathology providers reports that GP visits and pathology volumes remain well below the historical ...